BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

@article{Gorre2002BCRABLPM,
  title={BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.},
  author={M. E. Gorre and Katharine Ellwood-Yen and G. Chiosis and N. Rosen and C. Sawyers},
  journal={Blood},
  year={2002},
  volume={100 8},
  pages={
          3041-4
        }
}
  • M. E. Gorre, Katharine Ellwood-Yen, +2 authors C. Sawyers
  • Published 2002
  • Medicine, Biology
  • Blood
  • Clinical resistance to imatinib mesylate is commonly observed in patients with advanced Philadelphia chromosome- positive (Ph(+)) leukemias. Acquired resistance is typically associated with reactivation of BCR-ABL due to kinase domain mutations or gene amplification, indicating that BCR-ABL remains a viable target for inhibition in these patients. Strategies for overcoming resistance can be envisioned through exploitation of other molecular features of the BCR-ABL protein, such as its… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 27 REFERENCES